JP2005034154A - 完全ヒト抗体の調製 - Google Patents

完全ヒト抗体の調製 Download PDF

Info

Publication number
JP2005034154A
JP2005034154A JP2004207941A JP2004207941A JP2005034154A JP 2005034154 A JP2005034154 A JP 2005034154A JP 2004207941 A JP2004207941 A JP 2004207941A JP 2004207941 A JP2004207941 A JP 2004207941A JP 2005034154 A JP2005034154 A JP 2005034154A
Authority
JP
Japan
Prior art keywords
antibody
antigen
cells
cell
recognizes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004207941A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005034154A5 (https=
Inventor
Li-Te Chin
リ−テ チン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CCL Holdings Co Ltd
Original Assignee
CCL Holdings Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CCL Holdings Co Ltd filed Critical CCL Holdings Co Ltd
Publication of JP2005034154A publication Critical patent/JP2005034154A/ja
Publication of JP2005034154A5 publication Critical patent/JP2005034154A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2004207941A 2003-07-16 2004-07-14 完全ヒト抗体の調製 Pending JP2005034154A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/622,003 US20050014230A1 (en) 2003-07-16 2003-07-16 Preparation of fully human antibodies

Publications (2)

Publication Number Publication Date
JP2005034154A true JP2005034154A (ja) 2005-02-10
JP2005034154A5 JP2005034154A5 (https=) 2007-08-23

Family

ID=33477124

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004207941A Pending JP2005034154A (ja) 2003-07-16 2004-07-14 完全ヒト抗体の調製

Country Status (4)

Country Link
US (2) US20050014230A1 (https=)
EP (1) EP1498426A1 (https=)
JP (1) JP2005034154A (https=)
CN (1) CN1626669A (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010013498A1 (ja) 2008-08-01 2010-02-04 学校法人聖マリアンナ医科大学 変形性関節症治療剤又は予防剤
WO2011093082A1 (ja) 2010-01-29 2011-08-04 Ａｘｉｓ株式会社 変形性関節症治療剤または予防剤を製造するための使用
WO2011093081A1 (ja) 2010-01-29 2011-08-04 Ａｘｉｓ株式会社 変形性関節症治療剤を含有する注射剤
WO2011093083A1 (ja) 2010-01-29 2011-08-04 Ａｘｉｓ株式会社 変形性関節症治療又は予防用医薬組成物及びその製造方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102212133B (zh) * 2011-03-30 2013-01-16 中国医学科学院病原生物学研究所 人源HIV抗体的Fab片段及其编码基因与应用
FR2998579B1 (fr) 2012-11-27 2015-06-19 Commissariat Energie Atomique Methode pour obtenir des anticorps humains specifiques d'un antigene par immunisation in vitro
EP3030268B1 (en) 2013-08-09 2022-07-27 The Trustees Of The University Of Pennsylvania Combination of ifn-gamma with anti-erbb antibody for the treatment of cancers
US9840555B2 (en) * 2013-11-04 2017-12-12 Li-Te Chin Method for producing human monoclonal antibodies that binds to at least one part of HMGB1
CN103755805B (zh) * 2014-02-11 2015-08-12 中国疾病预防控制中心病毒病预防控制所 HIV-1 Env特异性的全人单克隆抗体
JP6403999B2 (ja) * 2014-06-05 2018-10-10 株式会社細川洋行 レトルト包装用積層体及び容器
AU2017345813B2 (en) * 2016-10-23 2024-06-13 Berkeley Lights, Inc. Methods for screening B cell lymphocytes
CN109157690A (zh) * 2018-06-15 2019-01-08 翁炳焕 猴-人细胞融合母胎血型不合治疗杂交株的制备
TW202231277A (zh) * 2019-05-21 2022-08-16 美商基利科學股份有限公司 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020632A1 (fr) * 1993-03-11 1994-09-15 Juridical Foundation The Chemo-Sero-Therapeutic R Esearch Insitute Anticorps monoclonal dirige contre le vih

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5215913A (en) * 1987-11-30 1993-06-01 Roger Williams General Hospital IgG-1 human monoclonal antibody reactive with an HIV-1 antigen and methods of use
US6309880B1 (en) * 1989-04-25 2001-10-30 Tanox, Inc. Antibodies specific for CD4-binding domain of HIV-1
AP237A (en) * 1990-05-29 1993-04-29 Cedars Sinai Medical Center Immunoreagents reactive with a conserved epitope of human immunodeficiency virus type 1 (HIV-1) gp120 and methods of use.
DE69435126D1 (de) * 1993-10-19 2008-10-02 Scripps Research Inst Synthetische humane neutralisierende monoklonale antikörper gegen hiv
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US6165463A (en) * 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US6391635B1 (en) * 1997-11-24 2002-05-21 Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
WO2001000678A1 (en) * 1999-06-30 2001-01-04 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies to hiv-1 envelope glycoprotein gp120

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020632A1 (fr) * 1993-03-11 1994-09-15 Juridical Foundation The Chemo-Sero-Therapeutic R Esearch Insitute Anticorps monoclonal dirige contre le vih

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010013498A1 (ja) 2008-08-01 2010-02-04 学校法人聖マリアンナ医科大学 変形性関節症治療剤又は予防剤
WO2011093082A1 (ja) 2010-01-29 2011-08-04 Ａｘｉｓ株式会社 変形性関節症治療剤または予防剤を製造するための使用
WO2011093081A1 (ja) 2010-01-29 2011-08-04 Ａｘｉｓ株式会社 変形性関節症治療剤を含有する注射剤
WO2011093083A1 (ja) 2010-01-29 2011-08-04 Ａｘｉｓ株式会社 変形性関節症治療又は予防用医薬組成物及びその製造方法
US9200077B2 (en) 2010-01-29 2015-12-01 Axis, Inc. Injectable solution containing therapeutic agent for osteoarthritis

Also Published As

Publication number Publication date
CN1626669A (zh) 2005-06-15
EP1498426A1 (en) 2005-01-19
US20080248531A1 (en) 2008-10-09
US20050014230A1 (en) 2005-01-20

Similar Documents

Publication Publication Date Title
US20080248531A1 (en) Preparation of fully human antibodies
US9290786B2 (en) Monoclonal antibody production by EBV transformation of B cells
EP0671920B1 (en) An anti-idiotypic antibody and its use in diagnosis and in therapy in hiv-related disease
AU2011201553B2 (en) Monoclonal antibody production by EBV transformation of B cells
JP2792733B2 (ja) ヒト免疫不全ウイルス型Ｉ（ＨＩＶ−１）ｇｐ１２０の保存エピトープと反応性のモノクローナル抗体
JP2626680B2 (ja) リンパ節障害関連ウイルスに対するヒト単クローン性抗体
US5695927A (en) Monoclonal antibodies specific for HIV and the hybridomas for production thereof
JP2888980B2 (ja) Ｈｉｖ免疫療法
EP0260691A2 (en) Immunotherapy for aids patients
US5981278A (en) Chimeric monoclonal antibodies which neutralize HIV-1 infection and their applications in therapy and prevention for AIDS
RU2603262C2 (ru) Композиции для предупреждения и/или лечения инфекции, вызванной вирусом вич-1
Chin et al. Site-directed primary in vitro immunization: production of HIV-1 neutralizing human monoclonal antibodies from lymphocytes obtained from seronegative donors
AU2011218704B2 (en) Monoclonal antibody production by EBV transformation of B cells
Neil et al. Immunization of SCID-Hu mice and generation of anti–hepatitis B surface antigen–specific hybridomas by electrofusion
JPH02503751A (ja) 狂犬病ウイルス細胞を特異的に認識するヒトモノクローナル抗体、それを産生する細胞、それを含有する処方物及びそれら全ての製造方法
JPH03505668A (ja) Ｇｐ４８に対する特異抗体
Wiseman et al. Cellular and antibody responses directed against the HIV-1 principal neutralizing domain in HIV-1-infected children
Alfonso et al. Human Anti-ganglioside IgG Antibody Response Induced by in vitro Immunization with Liposomes Containing GM3 (NeuGc) Ganglioside
JPH03292896A (ja) ヒト型２抗原特異性抗体および分泌細胞の作製方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070709

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070709

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20071207

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20071214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100511

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101019